Perspective
Managing food protein–induced enterocolitis syndrome during the coronavirus disease 2019 pandemic: Expert recommendations

https://doi.org/10.1016/j.anai.2020.04.032Get rights and content

Cited by (0)

Disclosures: Dr Nowak-Wegrzyn reports to have received research support from the National Institute of Allergy and Infectious Diseases, DBV Technologies, Astellas Pharma, and Danone and Nestle; received consultancy fees from Regeneron and Gerber Institute; serves as the deputy editor for the Annals of Allergy, Asthma, and Immunology; and serves as Chair of the Medical Advisory Board of the International Food Protein–Induced Enterocolitis Syndrome Association. Dr Fiocchi reports receiving research support from Danone, Sanofi, Hipp, Ferrero, and Galbusera S.p.A.; and has served on advisory boards for Danone, Stallergenes, Abbott, DBV, Novartis, Hipp, and International Food Protein–Induced Enterocolitis Syndrome Association. Dr Bird reports receiving research support from National Institute of Health–National Institute of Allergy and Infectious Diseases, Genentech, Food Allergy Research and Education, Aimmune Therapeutics, Astellas, and DBV Technologies; and has served on advisory boards for AllerGenis, Prota Therapeutics, and Food Allergy Research and Education. The remaining authors have no conflicts of interest to report.

Funding: The authors have no funding sources to report.

View Abstract